What Profits? Yet Another Troubling Leak At Teva Pharmaceutical Industries Limited

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Yet another leak is plaguing Teva Pharmaceuticals. This time, the drugmaker is chafing over a report in an Israeli business publication called The Marker that published an internal, five-year forecast showing that profits from its all-important Copaxone multiple sclerosis drug will drop 42 percent in 2014.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news